Insiders Revance Therapeutics, Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 11:06:44 2024-05-10 EDT			5-day change	1st Jan Change
3.105 ^USD	-27.62%		-21.27%	-64.62%

05-09	Earnings Flash (RVNC) REVANCE THERAPEUTICS Reports Q1 Revenue $51.9M, vs. Street Est of $56.7M	MT
05-09	Transcript : Revance Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

Revance Therapeutics, Inc. Announces Executive Changes	02-28	CI
Revance Therapeutics, Inc. Appoints Erica Jordan as Senior Vice President of Commercial to Chief Commercial Officer, Aesthetics	11-08	CI
Insider Sell: Revance Therapeutics	23-09-07	MT
Insider Sell: Revance Therapeutics	23-08-04	MT
Insider Sell: Revance Therapeutics	23-05-02	MT
Revance Therapeutics, Inc. Announces Board Changes	23-02-28	CI
Revance Therapeutics, Inc. Appoints David A. Hollander as Chief Medical Officer	22-10-17	CI
Insider Sell: Revance Therapeutics	22-09-16	MT
Revance Therapeutics, Inc. Announce Resignation of Aubrey Rankin as A Member of the Board of Directors	22-03-24	CI
Revance Therapeutics, Inc. Announces Executive Changes	22-02-28	CI
Insider Buy: Revance Therapeutics	21-11-30	MT
Revance Therapeutics, Inc. Promotes Dustin Sjuts as President	21-11-09	CI
Subsea 7 S A : Appoints Successor to Retiring CFO	21-09-14	MT
Insider Trends: Revance Therapeutics Insider Extends 90-Day Selling Trend	21-07-30	MT
Insider Trends: Revance Therapeutics Insider Extends 90-Day Selling Trend	21-07-28	MT
Revance Announces Board Changes	21-02-22	CI
Insider Trends: Insider 90-Day Selling Trend Extended at Revance Therapeutics	21-02-03	MT
Insider Trends: Insider Disposition Eases Back 90-Day Buy Trend at Revance Therapeutics	20-12-02	MT
Insider Trends: Revance Therapeutics Insider Sale Scales Back 90-Days of Buys	20-10-30	MT
Revance Therapeutics, Inc. Appoints Aubrey Rankin as Director and President of Innovation & Technology	20-07-24	CI

No results for this search